Comprehensive clinical imaging, histopathological analysis and liquid biopsy-based surveillance of human uveal melanoma in a prolonged rabbit xenograft model.
Journal
Melanoma research
ISSN: 1473-5636
Titre abrégé: Melanoma Res
Pays: England
ID NLM: 9109623
Informations de publication
Date de publication:
07 Jun 2024
07 Jun 2024
Historique:
medline:
7
6
2024
pubmed:
7
6
2024
entrez:
7
6
2024
Statut:
aheadofprint
Résumé
Uveal melanoma is the most common intraocular tumor in adults. Our group has previously developed a human uveal melanoma animal model; however, adverse effects caused by the immunosuppressive agent, cyclosporine A, prevented animals from surviving more than 12 weeks. In this study, we tested multiple cyclosporine A doses over an extended disease course up to 20 weeks, providing complete clinical imaging of intraocular tumors, histopathological analysis and liquid biopsy biomarker analysis. Twenty albino rabbits were divided into four groups with different daily cyclosporine A schedules (0-10 mg/kg) and inoculated with human uveal melanoma cell lines, 92.1 or MP41, into the suprachoroidal space. Rabbits were monitored with fundoscopy, ultrasound and optical coherence tomography. Intraocular tumors (macroscopic or microscopic) were detected in all study animals. Tumor size and growth were correlated to cyclosporine A dose, with tumors regressing when cyclosporine A was arrested. All tumors expressed HMB-45 and MelanA; however, tumor size, pigmentation and cell morphology differed in 92.1 vs. MP41 tumors. Finally, across all groups, circulating tumor DNA from plasma and aqueous humor was detected earlier than tumor detection by imaging and correlated to tumor growth. In conclusion, using three clinically relevant imaging modalities (fundoscopy, ultrasonography and optical coherence tomography) and liquid biopsy, we were successfully able to monitor tumor progression in our rabbit xenograft model of human uveal melanoma.
Identifiants
pubmed: 38847739
doi: 10.1097/CMR.0000000000000964
pii: 00008390-990000000-00154
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Amaro A, Gangemi R, Piaggio F, Angelini G, Barisione G, Ferrini S, et al. The biology of uveal melanoma. Cancer Metastasis Rev 2017; 36:109–140.
Smit KN, Jager MJ, Klein A. de, Kili E. Uveal melanoma: towards a molecular understanding. Prog Retin Eye Res 2019; 100800:1–15.
Damato B. Detection of uveal melanoma by optometrists in the United Kingdom. Ophthalmic Physiol Opt 2001; 21:268–271.
Chattopadhyay C, Kim DW, Gombos DS, Oba J, Qin Y, Williams MD, et al. Uveal melanoma: from diagnosis to treatment and the science in between. Cancer 2016; 122:2299–2312.
Kaliki S, Shields CL, Shields JA. Uveal melanoma: estimating prognosis. Indian J Ophthalmol 2015; 63:93–102.
Callejo SA, Antecka E, Blanco PL, Edelstein C, Burnier MN Jr. Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A prospective longitudinal study. Eye (Lond) 2007; 21:752–759.
Bustamante P, Piquet L, Landreville S, Burnier JV. Uveal melanoma pathobiology: metastasis to the liver. Semin Cancer Biol 2021; 71:65–85.
Shields CL, Say EAT, Hasanreisoglu M, Saktanasate J, Lawson BM, Landy JE, et al. Cytogenetic abnormalities in uveal melanoma based on tumor features and size in 1059 patients: the 2016 W. Richard Green Lecture. Ophthalmology 2017; 124:609–618.
Bustamante P, Tsering T, Coblentz J, Mastromonaco C, Abdouh M, Fonseca C, et al. Circulating tumor DNA tracking through driver mutations as a liquid biopsy-based biomarker for uveal melanoma. J Exp Clin Cancer Res 2021; 40:196.
Jin E, Burnier JV. Liquid biopsy in uveal melanoma: are we there yet? Ocul Oncol Pathol 2021; 7:1–16.
Grisanti S, Ranjbar M, Tura A, Heindl LM, Kakkassery V. [Uveal melanoma: early detection as the key to successful personalized medicine]. Ophthalmologe 2020; 117:508–520.
Singh AD, Bergman L, Seregard S. Uveal melanoma: epidemiologic aspects. Ophthalmol Clin North Am 2005; 18:75–84, viii.
Branisteanu DC, Bogdanici CM, Branisteanu DE, Maranduca MA, Zemba M, Balta F, et al. Uveal melanoma diagnosis and current treatment options (review). Exp Ther Med 2021; 22:1428.
Jager MJ, Shields CL, Cebulla CM, Abdel-Rahman MH, Grossniklaus HE, Stern MH, et al. Uveal melanoma. Nat Rev Dis Primers 2020; 6:24.
Labialle S, Dayan G, Gambrelle J, Gayet L, Barakat S, Devouassoux-Shisheboran M, et al. Characterization of the typical multidrug resistance profile in human uveal melanoma cell lines and in mouse liver metastasis derivatives. Melanoma Res 2005; 15:257–266.
Bérubé M, Deschambeault A, Boucher M, Germain L, Petitclerc E, Guérin SL. MMP-2 expression in uveal melanoma: differential activation status dictated by the cellular environment. Mol Vis 2005; 11:1101–1111.
Lapadula D, Farias E, Randolph CE, Purwin TJ, McGrath D, Charpentier TH, et al. Effects of oncogenic Galphaq and Galpha11 inhibition by FR900359 in uveal melanoma. Mol Cancer Res 2019; 17:963–973.
Jager MJ, Magner JA, Ksander BR, Dubovy SR. Uveal melanoma cell lines: where do they come from? (An American Ophthalmological Society Thesis). Trans Am Ophthalmol Soc 2016; 114:T5.
Amirouchene-Angelozzi N, Nemati F, Gentien D, Nicolas A, Dumont A, Carita G, et al. Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target. Mol Oncol 2014; 8:1508–1520.
Süsskind D, Hurst J, Rohrbach JM, Schnichels S. Novel mouse model for primary uveal melanoma: a pilot study. Clin Exp Ophthalmol 2017; 45:192–200.
Uner OE, Gandrakota N, Azarcon CP, Grossniklaus HE. Animal models of uveal melanoma. Ann Eye Sci 2022; 7:1–20.
Stei MM, Loeffler KU, Holz FG, Herwig MC. Animal models of uveal melanoma: methods, applicability, and limitations. Biomed Res Int 2016; 2016:4521807.
Blanco PL, Caissie AL, Burnier MN Jr. Experimental models of uveal melanoma. Can J Ophthalmol 2004; 39:441–447.
Blanco PL, Marshall JC, Antecka E, Callejo SA, Souza Filho JP, Saraiva V, et al. Characterization of ocular and metastatic uveal melanoma in an animal model. Invest Ophthalmol Vis Sci 2005; 46:4376–4382.
Blanco G, Saornil AM, Domingo E, Diebold Y, López R, Rábano G, et al. Uveal melanoma model with metastasis in rabbits: effects of different doses of cyclosporine A. Curr Eye Res 2000; 21:740–747.
de Waard-Siebinga I, Delft J.L. van, Wolff-Rouendaal D. de, Jager M. Hamster Greene melanoma in the rabbit eye: immunosuppressive treatment to improve this tumor model. Graefes Arch Clin Exp Ophthalmol 1994; 232:683–688.
De Waard-Siebinga I, Blom DJ, Griffioen M, Schrier PI, Hoogendoorn E, Beverstock G, et al. Establishment and characterization of an uveal-melanoma cell line. Int J Cancer 1995; 62:155–161.
Heegaard S, Jensen OA, Prause JU. Immunohistochemical diagnosis of malignant melanoma of the conjunctiva and uvea: comparison of the novel antibody against melan-A with S100 protein and HMB-45. Melanoma Res 2000; 10:350–354.
Shields CL, Kaliki S, Cohen MN, Shields PW, Furuta M, Shields JA. Prognosis of uveal melanoma based on race in 8100 patients: the 2015 Doyne Lecture. Eye (Lond) 2015; 29:1027–1035.
McLean IW, Keefe KS, Burnier MN. Uveal melanoma. Comparison of the prognostic value of fibrovascular loops, mean of the ten largest nucleoli, cell type, and tumor size. Ophthalmology 1997; 104:777–780.
Packard RB. Pattern of mortality in choroidal malignant melanoma. Br J Ophthalmol 1980; 64:565–575.
McLean MJ, Foster WD, Zimmerman LE. Prognostic factors in small malignant melanomas of choroid and ciliary body. Arch Ophthalmol 1977; 95:48–58.
Damato B. Progress in the management of patients with uveal melanoma. The 2012 Ashton Lecture. Eye (Lond) 2012; 26:1157–1172.
Barré-Sinoussi F, Montagutelli X. Animal models are essential to biological research: issues and perspectives. Future Sci OA 2015; 1:FSO63.
Liggett PE, Lo G, Pince KJ, Rao NA, Pascal SG, Kan-Mitchel J. Heterotransplantation of human uveal melanoma. Graefes Arch Clin Exp Ophthalmol 1993; 231:15–20.
Mak IW, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res 2014; 6:114–118.
de Jong M, Maina T. Of mice and humans: are they the same? Implications in cancer translational research. J Nucl Med 2010; 51:501–504.
Lallemand F, Schmitt M, Bourges JL, Gurny R, Benita S, Garrigue JS. Cyclosporine A delivery to the eye: a comprehensive review of academic and industrial efforts. Eur J Pharm Biopharm 2017; 117:14–28.
Periman LM, Mah FS, Karpecki PM. A review of the mechanism of action of cyclosporine A: the role of cyclosporine A in dry eye disease and recent formulation developments. Clin Ophthalmol 2020; 14:4187–4200.
Diehl R, Ferrara F, Müller C, Dreyer AY, McLeod DD, Fricke S, et al. Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches. Cell Mol Immunol 2017; 14:146–179.
Kines RC, Varsavsky I, Choudhary S, Bhattacharya D, Spring S, McLaughlin R, et al. An infrared dye-conjugated virus-like particle for the treatment of primary uveal melanoma. Mol Cancer Ther 2018; 17:565–574.
Ferns G, Reidy M, Ross R. Vascular effects of cyclosporine A in vivo and in vitro. Am J Pathol 1990; 137:403–413.
Tarlan B, Kiratli H. Uveal melanoma: current trends in diagnosis and management. Turk J Ophthalmol 2016; 46:123–137.
Hariri S, Moayed AA, Choh V, Bizheva K. In vivo assessment of thickness and reflectivity in a rat outer retinal degeneration model with ultrahigh resolution optical coherence tomography. Invest Ophthalmol Vis Sci 2012; 53:1982–1989.
Liu T, Li H, Song W, Jiao S, Zhang HF. Fundus camera guided photoacoustic ophthalmoscopy. Curr Eye Res 2013; 38:1229–1234.
Braun RD, Vistisen KS. Measurement of human choroidal melanoma xenograft volume in rats using high-frequency ultrasound. Invest Ophthalmol Vis Sci 2008; 49:16–22.
Papastefanou VP, Cohen VM. Uveal melanoma. J Skin Cancer 2011; 2011:573974.
Fuller DG, Snyder WB, Hutton WL, Vaiser A. Ultrasonographic features of choroidal malignant melanomas. Arch Ophthalmol 1979; 97:1465–1472.
Solnik M, Paduszyńska N, Czarnecka AM, Synoradzki KJ, Yousef YA, Chorągiewicz T, et al. Imaging of uveal melanoma-current standard and methods in development. Cancers (Basel) 2022; 14:3147.
Chen TC, Cense B, Pierce MC, Nassif N, Park BH, Yun SH, et al. Spectral domain optical coherence tomography: ultra-high speed, ultra-high resolution ophthalmic imaging. Arch Ophthalmol 2005; 123:1715–1720.
Alkin Z, Kashani AH, López-Jaime GR, Ruiz García H, Humayun MS, Sadda SR. Quantitative analysis of retinal structures using spectral domain optical coherence tomography in normal rabbits. Curr Eye Res 2013; 38:299–304.
Carpenter CL, Kim AY, Kashani AH. Normative retinal thicknesses in common animal models of eye disease using spectral domain optical coherence tomography. Adv Exp Med Biol 2018; 1074:157–166.
Terasawa H, Kinugasa H, Nouso K, Yamamoto S, Hirai M, Tanaka T, et al. Circulating tumor DNA dynamics analysis in a xenograft mouse model with esophageal squamous cell carcinoma. World J Gastroenterol 2021; 27:7134–7143.
Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010; 363:2191–2199.